Guard Therapeutics (Q3 Review): Waiting for the fog to lift - Redeye

Redeye provides a note following Guard’s Q3 report, which aligned with our expectations. We largely maintain our view for now as we await the full data readout from the POINTER study, together with the company’s forthcoming conclusions and strategic direction, which are expected shortly.

Länk till analysen i sin helhet: https://www.redeye.se/research/1138911/guard-therapeutics-q3-review-waiting-for-the-fog-to-lift?utm_source=finwire&utm_medium=RSS